CN Patent

CN112292135A — 用于治疗和预防严重眼表疾病的高分子量透明质酸

Assigned to 1 Com Medical Co ltd · Expires 2021-01-29 · 5y expired

What this patent protects

本发明涉及一种通过局部施用包含高分子量透明质酸的液体至人类或非人类动物受试者的眼睛的眼表来减少、预防或延迟严重眼表疾病发作，或预防或延迟轻度或中度眼表疾病发展成严重眼表疾病的方法，其中透明质酸的特性粘度大于2.5m 3 /kg且浓度小于0.2％w/v。

USPTO Abstract

本发明涉及一种通过局部施用包含高分子量透明质酸的液体至人类或非人类动物受试者的眼睛的眼表来减少、预防或延迟严重眼表疾病发作，或预防或延迟轻度或中度眼表疾病发展成严重眼表疾病的方法，其中透明质酸的特性粘度大于2.5m 3 /kg且浓度小于0.2％w/v。

Drugs covered by this patent

Patent Metadata

Patent number
CN112292135A
Jurisdiction
CN
Classification
—
Expires
2021-01-29
Drug substance claim
No
Drug product claim
No
Assignee
1 Com Medical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.